Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

(2009) Kalpit A Vora et al.   BMC IMMUNOLOGY

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads

(2008) Pieter Van der Veken et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: Isoindoline containing inhibitors

(2008) Sebastiaan Van Goethem et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

(2008) B. F. Burkey et al.   DIABETES OBESITY & METABOLISM

Beta cell mass in diabetes: a realistic therapeutic target?

(2008) J. J. Meier   DIABETOLOGIA

Stromal cell-derived factors 1α and 1β, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8

(2008) Katerina Ajami et al.   FEBS LETTERS

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

(2008) William J. Metzler et al.   PROTEIN SCIENCE

Fibroblast activation protein and chronic liver disease

(2007) Xin Maggie Wang   Frontiers in Bioscience-Landmark